It was shown that the survival of CML-LSCs depends on EZH2 expression and more precisely the enzymatic activity of EZH2, while its inactivation influences LSC survival and inhibits disease from initiation and maintenance.95 The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.